We have released Veridical, which uses transcriptomic data to assess evidence for all predicted splicing mutations in a genome, exome or gene panels. This software has been integrated into our new MutationForecaster webservice. To validate splicing mutations predicted by the Shannon pipeline, a set of gene variants and RNASeq data from the same individual are uploaded. The online version features built-in controls, automated analyses, and directly returns results to users.
Commercial, long term, multi-seat licenses and installation support for the standalone version are also available. Contact Cytognomix.
Previous trial users of Veridical may register with MutationForecaster. After logging in, subscriptions to use Veridical and all other products can be activated through the Account menu on the system.
Watch C. Viner’s award winning presentation at 2014 Compute Ontario Research Day:
Veridical is patent pending.
- February 27, 2017. CytoGnomix finalizes contract with Government of Canada
- Jan. 28, 2017. New version of F1000Research paper on chemotherapy response in breast cancer
- January 25, 2017. Comment from the Transforming Genetic Medicine Initiative Blog
- Jan. 23, 2017. Automated interpretation of digital pathology images is currently at an embryonic stage of development